Bespoke Extracts (BSPK) Cash from Financing Activities (2011 - 2025)
Bespoke Extracts' (BSPK) quarterly Cash from Financing Activities came in at $35000.0 in Q3 2025, up 40.0% year-on-year from $25000.0 in Q3 2024, and up 1650.0% quarter-over-quarter from $2000.0 in Q2 2025.
Bespoke Extracts (BSPK) Cash from Financing Activities (2011 - 2025) Analysis & Trends
Bespoke Extracts has disclosed Cash from Financing Activities across 14 years of filings, most recently posting $35000.0 for Q3 2025.
- Cash from Financing Activities for Q3 2025 came in at $35000.0, up 40.0% year-over-year; the trailing twelve-month figure through Sep 2025 was $255000.0 (up 30.85% YoY), and the FY2024 annual result was $343500.0, down 13.56% from the prior year.
- Cash from Financing Activities came in at $35000.0 for Q3 2025 at Bespoke Extracts, up from $2000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $600000.0 in Q1 2021 to a low of -$8957.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is $126099.5 (2022), against an average of $152286.1.
- Across the five-year window, Cash from Financing Activities sank 105.6% in 2023 and soared 563.51% in 2024, its largest moves.
- Bespoke Extracts' Cash from Financing Activities stood at $25000.0 in 2021, then surged by 922.01% to $255502.0 in 2022, then sank by 89.68% to $26375.0 in 2023, then jumped by 563.51% to $175000.0 in 2024, then tumbled by 80.0% to $35000.0 in 2025.
- The last three Cash from Financing Activities figures came in at $35000.0 (Q3 2025), $2000.0 (Q2 2025), and $43000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Bespoke Extracts | - | - | 234,175.00 | 35,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 35,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | 175,000.00 |
| Dec 31, 2024 | 175,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 38,500.00 |
| Jun 30, 2024 | 38,500.00 |
| Mar 31, 2024 | 105,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Dec 31, 2023 | 26,375.00 |
| Dec 31, 2023 | 26,375.00 |
| Sep 30, 2023 | -8,957.00 |
| Sep 30, 2023 | -8,957.00 |
| Jun 30, 2023 | 192,954.00 |
| Jun 30, 2023 | 192,954.00 |